{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:15Z","timestamp":1792782855932,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Roche Pharmaceuticals Co., Ltd.,"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Given the limited tocilizumab (TCZ) treatment data for systemic juvenile idiopathic arthritis (sJIA) in China, we evaluated the long-term efficacy and safety of TCZ in Chinese patients with sJIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In this multicentre, interventional Phase IV study, patients with sJIA and inadequate clinical response to non-steroidal anti-inflammatory drugs\/corticosteroids received TCZ infusions every 2\u00a0weeks based on body weight (&lt;\u200930\u00a0kg, 12\u00a0mg\/kg;\u2009\u2265\u200930\u00a0kg, 8\u00a0mg\/kg), over a 52-week open-label period and an 8-week safety follow-up period. The primary endpoint was the proportion of patients with a JIA American College of Rheumatology (ACR) 30 response and absence of fever at Week 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-two patients were enrolled and treated (12-mg\/kg group, 34; 8-mg\/kg group, 28). At Week 12, 87.1% (95% confidence interval 78.8%\u201395.4%) of patients had JIA ACR 30 response and absence of fever; Week 52 results were similar. The proportion of JIA ACR 30\/50\/70\/90 responders rapidly increased at Week 12, up to Week 52. High-sensitivity C-reactive protein (hsCRP) levels decreased within 4\u00a0weeks; 44\/58 patients (75.9%) with elevated baseline hsCRP recovered at Week 52. Childhood Health Assessment Questionnaire pain scores, disability index scores, and mean corticosteroid dose decreased over time. Height standard deviation score changes at Week 52 indicated catch-up growth. Most adverse events (AEs) were mild (serious AE incidence, 17.7%). No deaths or macrophage activation syndrome occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first multicentre trial to report the efficacy and safety of TCZ in Chinese patients with sJIA at 52\u00a0weeks. No new safety concerns were found.<\/jats:p>\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"3\">\n                              <jats:bold>Key points<\/jats:bold>\n                              <jats:italic>\u2022 This is the first multicentre trial providing strong evidence for tocilizumab (TCZ) treatment for systemic juvenile idiopathic arthritis (sJIA) in China.<\/jats:italic>\n                              <jats:italic>\u2022 The study reported TCZ had good efficacy and favourable safety profiles in Chinese sJIA patients in the long term (52 weeks).<\/jats:italic>\n                              <jats:italic>\u2022 TCZ treatment showed rapid disease control, which was maintained over time, catch-up growth benefits in patients, tapering and discontinuation of corticosteroids, and improved quality of life.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-024-07126-9","type":"journal-article","created":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T22:01:57Z","timestamp":1726437717000},"page":"3457-3467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8217-6765","authenticated-orcid":false,"given":"Caifeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"7126_CR1","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1093\/rheumatology\/keab948","volume":"61","author":"M Pardeo","year":"2022","unstructured":"Pardeo M, Vastert SJ, De Benedetti F (2022) It is about time: the first validated biomarker for early diagnosis of systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 61:2724\u20132725","journal-title":"Rheumatology (Oxford)"},{"key":"7126_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.pcl.2018.04.005","volume":"65","author":"JJY Lee","year":"2018","unstructured":"Lee JJY, Schneider R (2018) Systemic juvenile idiopathic arthritis. Pediatr Clin North Am 65:691\u2013709","journal-title":"Pediatr Clin North Am"},{"key":"7126_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I et al (2014) Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 81:112\u2013117","journal-title":"Joint Bone Spine"},{"key":"7126_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/B978-0-323-24145-8.00016-8","volume-title":"Textbook of pediatric rheumatology","author":"F De Benedetti","year":"2016","unstructured":"De Benedetti F, Schneider R (2016) Chapter 16 - Systemic juvenile idiopathic arthritis. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR (eds) Textbook of pediatric rheumatology, 7th edn. W.B. Saunders, Philadelphia, pp 205\u201316.e6","edition":"7"},{"key":"7126_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/art.41107","volume":"72","author":"C Kessel","year":"2020","unstructured":"Kessel C, Hedrich CM, Foell D (2020) Innately adaptive or truly autoimmune: is there something unique about systemic juvenile idiopathic arthritis? Arthritis Rheumatol 72:210\u2013219","journal-title":"Arthritis Rheumatol"},{"key":"7126_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12969-021-00629-8","volume":"19","author":"LN Zaripova","year":"2021","unstructured":"Zaripova LN, Midgley A, Christmas SE et al (2021) Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J 19:135","journal-title":"Pediatr Rheumatol Online J"},{"key":"7126_CR7","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/art.21774","volume":"54","author":"D Singh-Grewal","year":"2006","unstructured":"Singh-Grewal D, Schneider R, Bayer N et al (2006) Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 54:1595\u20131601","journal-title":"Arthritis Rheum"},{"key":"7126_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semarthrit.2017.11.002","volume":"48","author":"F McErlane","year":"2018","unstructured":"McErlane F, Carrasco R, Kearsley-Fleet L et al (2018) Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS). Semin Arthritis Rheum 48:53\u201360","journal-title":"Semin Arthritis Rheum"},{"key":"7126_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/25785826.2021.1912893","volume":"44","author":"M Shimizu","year":"2021","unstructured":"Shimizu M (2021) Macrophage activation syndrome in systemic juvenile idiopathic arthritis. Immunol Med 44:237\u2013245","journal-title":"Immunol Med"},{"key":"7126_CR10","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/art.1780340912","volume":"34","author":"F de Benedetti","year":"1991","unstructured":"de Benedetti F, Massa M, Robbioni P et al (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34:1158\u20131163","journal-title":"Arthritis Rheum"},{"key":"7126_CR11","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1210\/endo.142.11.8511","volume":"142","author":"F De Benedetti","year":"2001","unstructured":"De Benedetti F, Meazza C, Oliveri M et al (2001) Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142:4818\u20134826","journal-title":"Endocrinology"},{"key":"7126_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy EH, De Benedetti F, Takeuchi T et al (2020) Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16:335\u2013345","journal-title":"Nat Rev Rheumatol"},{"key":"7126_CR13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","volume":"7","author":"ED Mellins","year":"2011","unstructured":"Mellins ED, Macaubas C, Grom AA (2011) Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 7:416\u2013426","journal-title":"Nat Rev Rheumatol"},{"key":"7126_CR14","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385\u201395 (Erratum in: N Engl J Med 2015;372:887)","journal-title":"N Engl J Med"},{"key":"7126_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ et al (2022) 2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol 74:553\u2013569","journal-title":"Arthritis Rheumatol"},{"key":"7126_CR16","unstructured":"Ruperto N, Ravelli A, Pistorio A, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001;19:S1\u20139."},{"key":"7126_CR17","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","volume":"75","author":"S Yokota","year":"2016","unstructured":"Yokota S, Itoh Y, Morio T et al (2016) Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 75:1654\u20131660","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07126-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T05:05:24Z","timestamp":1729227924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07126-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["7126"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07126-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"Yuxiu Kong and Jiahui Xu are employees of Shanghai Roche Pharmaceuticals Co., Ltd., the study sponsor. The other authors have disclosed no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}